Abstract:Synthetic peptide‐based vaccine strategies are reviewed in the context of anticancer intervention, focusing on critical aspects such as peptide epitope selection, adjuvant integration, and nuanced classification of synthetic peptide cancer vaccines. The potential synergy of peptide‐based vaccines with common therapeutics in cancer is also considered. The present review focuses on synthetic peptide‐based vaccine strategies in the context of anticancer intervention, paying attention to critical aspects such as peptide epitope selection, adjuvant integration, and nuanced classification of synthetic peptide cancer vaccines. Within this discussion, we delve into the diverse array of synthetic peptide‐based anticancer vaccines, each derived from tumor‐associated antigens (TAAs), including melanoma antigen recognized by T cells 1 (Melan‐A or MART‐1), mucin 1 (MUC1), human epidermal growth factor receptor 2 (HER‐2), tumor protein 53 (p53), human telomerase reverse transcriptase (hTERT), survivin, folate receptor (FR), cancer‐testis antigen 1 (NY‐ESO‐1), and prostate‐specific antigen (PSA). We also describe the synthetic peptide‐based vaccines developed for cancers triggered by oncovirus, such as human papillomavirus (HPV), and hepatitis C virus (HCV). Additionally, the potential synergy of peptide‐based vaccines with common therapeutics in cancer was considered. The last part of our discussion deals with the realm of the peptide‐based vaccines delivery, highlighting its role in translating the most promising candidates into effective clinical strategies. Although this discussion does not cover all the ongoing peptide vaccine investigations, it aims at offering valuable insights into the chemical modifications and the structural complexities of anticancer peptide‐based vaccines.

Progress in Synthetic Peptide Vaccine

Current Status and Future Developments in Synthetic Peptides

Virus-Derived Peptides for Clinical Applications

Synthetic peptide vaccines: unexpected fulfillment of discarded hope?

“De Novo” Engineering of Peptide Immunogenic and Antigenic Determinants as Potential Vaccines

Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection

Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines

The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

Chemical Synthesis of Glycans and Applications in Carbohydrate-Based Vaccines

Review on therapeutic potential of peptides: Advancements in synthesis methods, linear and cyclic peptides, and strategies for overcoming challenges

A novel method for synthetic vaccine construction based on protein assembly

Protein and Peptide Biomaterials for Engineered Subunit Vaccines and Immunotherapeutic Applications

Personalized Neoantigen Vaccination with Synthetic Long Peptides: Recent Advances and Future Perspectives

Analysis of the development prospects of cancer therapeutic vaccines based on the current research status of peptide vaccines

Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

Automated Peptide Synthesizers and Glycoprotein Synthesis

Research progress of transgenic plant-derived vaccines

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

The application of self-assembled nanostructures in peptide-based subunit vaccine development

Recent advances in self-assembled peptides: Implications for targeted drug delivery and vaccine engineering

Recent Progress in Solid‐Phase Total Synthesis of Naturally Occurring Small Peptides